BETRF
BetterLife Pharma Inc.
Price Chart
Latest Quote
$0.05
+0.00 (+0.00%)
Current Price
| Previous Close | $0.05 |
| Open | $0.05 |
| Day High | $0.05 |
| Day Low | $0.05 |
| Volume | 3,000 |
Stock Information
Note: Financial values converted from CAD to USD
| Shares Outstanding | 161.79M |
| Total Debt | $584K |
| Cash Equivalents | $9K |
| Net Income | $-1.08M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $7.62M |
| EPS (TTM) | $-0.01 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $10.95M |
| Income | $-1.08M |
| Book/sh | $-0.05 |
| Cash/sh | $0.00 |
Financial Ratios
| Quick Ratio | 0.00 |
| Current Ratio | 0.03 |
Returns & Margins
| ROA | -508.19% |
Ownership
| Insider Ownership | 33.34% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -1.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| SMA200 | $nan |
| RSI | 50.00 |
| ATR | nan |
| Shares Float | 101.45M |
| Rel Volume | 0.10 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| Year | nan% |
| 3 Years | nan% |
| 5 Years | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-04 | $nan | 3,000 |
| 2026-06-03 | $0.05 | 151,600 |
| 2026-06-02 | $0.04 | 32,200 |
| 2026-06-01 | $0.05 | 10,300 |
| 2026-05-29 | $0.05 | 177,400 |
| 2026-05-28 | $0.05 | 2,000 |
| 2026-05-27 | $0.05 | 1,000 |
| 2026-05-26 | $0.05 | 3,400 |
| 2026-05-22 | $0.05 | 0 |
| 2026-05-21 | $0.05 | 20,400 |
| 2026-05-20 | $0.05 | 40,500 |
| 2026-05-19 | $0.05 | 10,200 |
| 2026-05-18 | $0.05 | 6,600 |
| 2026-05-15 | $0.05 | 34,400 |
| 2026-05-14 | $0.05 | 77,300 |
| 2026-05-13 | $0.05 | 34,000 |
| 2026-05-12 | $0.05 | 0 |
| 2026-05-11 | $0.05 | 5,000 |
| 2026-05-08 | $0.05 | 14,300 |
| 2026-05-07 | $0.05 | 0 |
| 2026-05-06 | $0.05 | 12,200 |
| 2026-05-05 | $0.05 | 0 |
About BetterLife Pharma Inc.
BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety disorder, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat anxiety related disorders, including benzodiazepine dependency. It is also developing MM-001, a topical cream formulation of interferon-alpha 2b, which has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation that has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
đ° Latest News
No news articles available at the moment. Check back later for updates on BETRF.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $319,474 | $50,897 | $67,178 | $58,345 |
| Total Expenses | $4,724,931 | $3,209,889 | $9,257,441 | $9,969,619 |
| Other Income Expense | $663,687 | $396,326 | $-24,236 | $-740,022 |
| Other Non Operating Income Expenses | $305,446 | $-34,687 | $113,109 | $-317,559 |
| Net Non Operating Interest Income Expense | $439,360 | $-84,947 | $-91,095 | $-1,282,867 |
| Total Other Finance Cost | $-758,834 | $34,050 | $23,917 | $1,224,522 |
| Interest Expense Non Operating | $319,474 | $50,897 | $67,178 | $58,345 |
| Operating Expense | $4,724,931 | $3,209,889 | $9,257,441 | $9,969,619 |
| Selling And Marketing Expense | $0 | $0 | $123,219 | $437,689 |
| General And Administrative Expense | $4,300,594 | $2,638,942 | $6,438,501 | $4,092,860 |
| Rent Expense Supplemental | - | - | $0 | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,520,288 | $-2,889,032 | $-9,016,201 | $-12,159,174 |
| Net Interest Income | $439,360 | $-84,947 | $-91,095 | $-1,282,867 |
| Normalized Income | $-3,878,529 | $-3,320,045 | $-8,878,856 | $-11,847,439 |
| Net Income From Continuing And Discontinued Operation | $-3,520,288 | $-2,889,032 | $-9,016,201 | $-12,159,174 |
| Total Operating Income As Reported | $-5,000,113 | $-3,240,241 | $-9,460,653 | $-10,207,825 |
| Net Income Common Stockholders | $-3,520,288 | $-2,889,032 | $-9,016,201 | $-12,159,174 |
| Net Income | $-3,520,288 | $-2,889,032 | $-9,016,201 | $-12,159,174 |
| Net Income Including Noncontrolling Interests | $-3,621,884 | $-2,898,510 | $-9,372,772 | $-12,159,174 |
| Net Income Continuous Operations | $-3,621,884 | $-2,898,510 | $-9,372,772 | $-12,159,174 |
| Pretax Income | $-3,621,884 | $-2,898,510 | $-9,372,772 | $-11,992,508 |
| Special Income Charges | $666,859 | $599,129 | $60,505 | $-315,507 |
| Operating Income | $-4,724,931 | $-3,209,889 | $-9,257,441 | $-9,969,619 |
| Depreciation Amortization Depletion Income Statement | $0 | $0 | $18,435 | $18,436 |
| Depreciation And Amortization In Income Statement | $0 | $0 | $18,435 | $18,436 |
| Depreciation Income Statement | $0 | $0 | $18,435 | $18,436 |
| Interest Income | - | - | $0 | $0 |
| Interest Income Non Operating | - | - | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $-0.03 | $-0.03 | $-0.10 | $-0.16 |
| Basic EPS | $-0.03 | $-0.03 | $-0.10 | $-0.16 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-110,728 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,660,651 | $-3,278,626 | $-9,149,814 | $-11,493,264 |
| Total Unusual Items | $358,241 | $431,013 | $-137,345 | $-422,463 |
| Total Unusual Items Excluding Goodwill | $358,241 | $431,013 | $-137,345 | $-422,463 |
| Reconciled Depreciation | $0 | $0 | $18,435 | $18,436 |
| EBITDA (Bullshit earnings) | $-3,302,410 | $-2,847,613 | $-9,287,159 | $-11,915,727 |
| EBIT | $-3,302,410 | $-2,847,613 | $-9,305,594 | $-11,934,163 |
| Diluted Average Shares | $123,865,739 | $109,285,957 | $86,560,760 | $75,469,531 |
| Basic Average Shares | $123,865,739 | $109,285,957 | $86,560,760 | $75,469,531 |
| Diluted NI Availto Com Stockholders | $-3,520,288 | $-2,889,032 | $-9,016,201 | $-12,159,174 |
| Minority Interests | $101,596 | $9,478 | $356,571 | $0 |
| Other Special Charges | $-666,859 | $-599,129 | $-60,505 | $507,206 |
| Gain On Sale Of Security | $-308,618 | $-168,116 | $-197,850 | $-106,956 |
| Research And Development | $424,337 | $570,947 | $2,677,286 | $5,420,634 |
| Selling General And Administration | $4,300,594 | $2,638,942 | $6,561,720 | $4,530,549 |
| Other Gand A | $1,882,262 | $1,198,044 | $4,705,730 | $2,350,458 |
| Salaries And Wages | $2,418,332 | $1,440,898 | $1,732,771 | $1,742,402 |
| Tax Provision | - | $0 | $0 | $166,666 |
| Gain On Sale Of Ppe | - | $0 | $0 | $191,699 |
| Impairment Of Capital Assets | - | - | $0 | $0 |
| Restructuring And Mergern Acquisition | - | - | $0 | $0 |
| Rent And Landing Fees | - | - | $0 | $0 |
| Write Off | - | - | - | $0 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-10,677,529 | $-10,808,521 | $-10,728,221 | $-3,880,858 |
| Total Assets | $224,963 | $324,746 | $74,727 | $1,161,363 |
| Total Non Current Assets | $0 | $0 | $0 | $18,435 |
| Current Assets | $224,963 | $324,746 | $74,727 | $1,142,928 |
| Other Current Assets | $205,139 | $247,826 | $49,224 | $644,422 |
| Receivables | $11,644 | $39,536 | $17,196 | $324,993 |
| Accounts Receivable | $11,644 | $39,536 | $17,196 | $324,993 |
| Cash Cash Equivalents And Short Term Investments | $8,180 | $37,384 | $8,307 | $173,513 |
| Cash And Cash Equivalents | $8,180 | $37,384 | $8,307 | $173,513 |
| Cash Financial | $8,180 | $37,384 | $8,307 | $173,513 |
| Goodwill And Other Intangible Assets | - | - | $0 | $0 |
| Prepaid Assets | - | - | $49,224 | $644,422 |
| Debt | ||||
| Net Debt | $911,540 | $290,345 | $71,693 | $138,926 |
| Total Debt | $1,302,148 | $1,468,991 | $1,187,212 | $1,395,734 |
| Long Term Debt And Capital Lease Obligation | $49,115 | $673,365 | $440,170 | $899,074 |
| Long Term Debt | $49,115 | $82,495 | - | $34,559 |
| Current Debt And Capital Lease Obligation | $1,253,033 | $795,626 | $747,042 | $496,660 |
| Current Debt | $870,605 | $245,234 | $80,000 | $277,880 |
| Other Current Borrowings | $870,605 | $245,234 | $80,000 | $277,880 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,587,112 | $8,020,513 | $7,608,197 | $5,042,221 |
| Total Non Current Liabilities Net Minority Interest | $49,116 | $673,365 | $460,870 | $899,074 |
| Other Non Current Liabilities | $1 | - | - | - |
| Current Liabilities | $7,537,996 | $7,347,148 | $7,147,327 | $4,143,147 |
| Other Current Liabilities | $312,936 | $279,500 | - | $353 |
| Payables And Accrued Expenses | $5,972,027 | $6,272,022 | $6,400,285 | $3,646,134 |
| Payables | $5,972,027 | $6,272,022 | $6,400,285 | $3,646,134 |
| Accounts Payable | $4,495,327 | $4,976,823 | $5,436,024 | $3,341,261 |
| Derivative Product Liabilities | - | $275,032 | $20,700 | $0 |
| Total Tax Payable | - | - | $0 | $160,006 |
| Income Tax Payable | - | - | $0 | $160,006 |
| Equity | ||||
| Common Stock Equity | $-10,677,529 | $-10,808,521 | $-10,728,221 | $-3,880,858 |
| Total Equity Gross Minority Interest | $-7,362,149 | $-7,695,767 | $-7,533,470 | $-3,880,858 |
| Stockholders Equity | $-10,677,529 | $-10,808,521 | $-10,728,221 | $-3,880,858 |
| Other Equity Interest | $43,100 | - | $74,000 | - |
| Gains Losses Not Affecting Retained Earnings | $27,910,014 | $25,807,602 | $24,812,945 | $23,905,113 |
| Other Equity Adjustments | $27,910,014 | $25,807,602 | $24,812,945 | $23,905,113 |
| Retained Earnings | $-118,596,001 | $-115,075,713 | $-112,186,681 | $-103,170,480 |
| Other | ||||
| Ordinary Shares Number | $129,573,385 | $115,825,302 | $90,103,873 | $85,241,238 |
| Share Issued | $129,573,385 | $115,825,302 | $90,103,873 | $85,241,238 |
| Tangible Book Value | $-10,677,529 | $-10,808,521 | $-10,728,221 | $-3,880,858 |
| Invested Capital | $-9,757,809 | $-10,480,792 | $-10,648,221 | $-3,568,419 |
| Working Capital | $-7,313,033 | $-7,022,402 | $-7,072,600 | $-3,000,219 |
| Capital Lease Obligations | $382,428 | $1,141,262 | $1,107,212 | $1,083,295 |
| Total Capitalization | $-10,628,414 | $-10,726,026 | $-10,728,221 | $-3,846,299 |
| Minority Interest | $3,315,380 | $3,112,754 | $3,194,751 | $0 |
| Capital Stock | $79,965,358 | $78,459,590 | $76,571,515 | $75,384,509 |
| Common Stock | $79,965,358 | $78,459,590 | $76,571,515 | $75,384,509 |
| Long Term Capital Lease Obligation | $0 | $590,870 | $440,170 | $864,515 |
| Current Capital Lease Obligation | $382,428 | $550,392 | $667,042 | $218,780 |
| Dueto Related Parties Current | $1,476,700 | $1,295,199 | $964,261 | $144,867 |
| Net PPE | $0 | $0 | $0 | $18,435 |
| Accumulated Depreciation | $-44,553 | $-44,553 | $-44,553 | $-26,118 |
| Gross PPE | $44,553 | $44,553 | $44,553 | $44,553 |
| Other Properties | $44,553 | $44,553 | $44,553 | $44,553 |
| Leases | - | - | $0 | $0 |
| Machinery Furniture Equipment | - | - | $0 | $0 |
| Properties | - | - | $0 | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,021,752 | $-2,472,410 | $-1,503,512 | $-11,202,820 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,021,752 | $-2,472,410 | $-1,503,512 | $-11,202,820 |
| Cash Flow From Continuing Operating Activities | $-2,021,752 | $-2,472,410 | $-1,503,512 | $-11,202,820 |
| Operating Gains Losses | $198,399 | $-305,175 | $395,055 | $50,692 |
| Investing Activities | ||||
| Investing Cash Flow | - | - | $0 | $0 |
| Cash Flow From Continuing Investing Activities | - | - | $0 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $705,000 | $2,201,543 | $833,313 | $11,440,705 |
| Financing Cash Flow | $1,992,540 | $2,501,543 | $1,335,889 | $11,233,521 |
| Cash Flow From Continuing Financing Activities | $1,992,540 | $2,501,543 | $1,335,889 | $11,233,521 |
| Net Other Financing Charges | $63,340 | - | $502,576 | $-77,184 |
| Net Common Stock Issuance | $705,000 | $2,201,543 | $833,313 | $11,440,705 |
| Common Stock Issuance | $705,000 | $2,201,543 | $833,313 | $11,440,705 |
| Other | ||||
| Issuance Of Debt | $1,224,200 | $300,000 | $0 | $120,000 |
| End Cash Position | $8,180 | $37,384 | $8,307 | $173,513 |
| Beginning Cash Position | $37,384 | $8,307 | $173,513 | $154,722 |
| Effect Of Exchange Rate Changes | $8 | $-56 | $2,417 | $-11,910 |
| Changes In Cash | $-29,212 | $29,133 | $-167,623 | $30,701 |
| Net Issuance Payments Of Debt | $1,224,200 | $300,000 | $0 | $-130,000 |
| Net Long Term Debt Issuance | $1,224,200 | $300,000 | $0 | $-130,000 |
| Long Term Debt Issuance | $1,224,200 | $300,000 | $0 | $120,000 |
| Change In Working Capital | $752,867 | $321,609 | $3,433,529 | $-1,316,404 |
| Change In Payables And Accrued Expense | $682,268 | $542,562 | $2,528,324 | $-1,507,721 |
| Change In Payable | $682,268 | $542,562 | $2,528,324 | $-1,507,721 |
| Change In Account Payable | $108,830 | $-701,563 | $2,212,993 | $-1,157,595 |
| Change In Tax Payable | $0 | $0 | $-160,006 | $166,667 |
| Change In Income Tax Payable | $0 | $0 | $-160,006 | $166,667 |
| Change In Prepaid Assets | $42,688 | $-198,603 | $595,198 | $10,288 |
| Change In Receivables | $27,911 | $-22,350 | $310,007 | $181,029 |
| Other Non Cash Items | $-1,401,059 | $-90,597 | $3,071,176 | $972,230 |
| Stock Based Compensation | $2,049,925 | $500,263 | $951,065 | $1,231,400 |
| Depreciation Amortization Depletion | $0 | $0 | $18,435 | $18,436 |
| Depreciation And Amortization | $0 | $0 | $18,435 | $18,436 |
| Depreciation | $0 | $0 | $18,435 | $18,436 |
| Gain Loss On Investment Securities | $33,436 | $137,764 | $-5,362 | $-131,250 |
| Net Foreign Currency Exchange Gain Loss | $275,182 | $26,190 | $203,212 | $238,206 |
| Net Income From Continuing Operations | $-3,621,884 | $-2,898,510 | $-9,372,772 | $-12,159,174 |
| Repayment Of Debt | - | - | $0 | $-250,000 |
| Interest Paid Supplemental Data | - | - | $0 | $0 |
| Proceeds From Stock Option Exercised | - | - | $0 | $0 |
| Net Short Term Debt Issuance | - | - | $0 | $-250,000 |
| Long Term Debt Payments | - | - | $0 | $-250,000 |
| Net Business Purchase And Sale | - | - | $0 | $0 |
| Sale Of Business | - | - | $0 | $0 |
| Net Intangibles Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Intangibles | - | - | $0 | $0 |
| Net PPE Purchase And Sale | - | - | $0 | $0 |
| Purchase Of PPE | - | - | $0 | $0 |
| Asset Impairment Charge | - | - | $0 | $0 |
| Purchase Of Business | - | - | - | $0 |
Fetched: 2026-02-02